Angioimmunoblastic T-cell Lymphoma: Clinical Characteristics and Treatment Outcomes

Abstract Purpose The aim of this study was to explore the prognostic value of baseline metabolic parameters of 18F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma (AITL). Materials and methods Fifty-six AITL patients (average age 64.0 ± 1.3 years) diagnosed pathologically from August 2009 to August 2019 were enrolled in this retrospective study. The total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), and correlated clinical characteristics were collected and analysed. TMTV was computed with the 41% SUVmax threshold method. The chi-square test or Fisher’s exact probability method was used to compare clinical characteristics. Kaplan–Meier curves were used to describe progression-free survival (PFS) and overall survival (OS). The log-rank test was used to analyse the difference within groups. The statistically significant factors in the univariate regression analysis were incorporated into the Cox risk proportional regression model for multivariate survival analysis. Results The TMTV cut-off value was 514.6 cm3 from the ROC curve analysis. Forty (71.4%) patients progressed and 31 (55.4%) patients died within a median follow-up time of 19.1 (interquartile range 7.8–34.6) months. The 1-year and 3-year PFS rates were 42.9% and 30.1%, and the 3-year and 5-year OS rates were 45.9% and 34.4%, respectively. Univariate survival analysis showed that high TMTV and TLG may be the factors contributing to poor PFS and OS. Multivariate analysis showed that TMTV and prognostic index for T-cell lymphoma (PIT) were independent parameters for PFS and OS in AITL patients. TMTV, combined with PIT, may have better risk stratification performance than TMTV alone. Conclusions Baseline TMTV and PIT were independent prognostic predictors in AITL patients. The combination of TMTV and PIT can facilitate prognostic stratification and contribute to personalized therapy.

Download Full-text

Clinical Characteristics and Treatment Outcomes of Non-anaplastic Peripheral T-Cell Lymphoma in Children and Adolescents: A Single-center Experience

Clinical Pediatric Hematology-Oncology ◽

10.15264/cpho.2015.22.2.104 ◽

2015 ◽

Vol 22 (2) ◽

pp. 104-111 ◽

Cited By ~ 1

Author(s):

Darae Lee ◽

Kyung-Nam Koh ◽

Yejee Byun ◽

Hyun jin Kim ◽

Jin Kyung Suh ◽

...

Keyword(s):

T Cell ◽

Children And Adolescents ◽

Treatment Outcomes ◽

Clinical Characteristics ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Single Center ◽

Peripheral T Cell Lymphoma ◽

Single Center Experience

Download Full-text

Clinical Features and Treatment Outcomes of Angioimmunoblastic T-Cell Lymphoma: An Analysis from a Nationwide Multicenter Registry, Thailand

Blood ◽

10.1182/blood.v126.23.5064.5064 ◽

2015 ◽

Vol 126 (23) ◽

pp. 5064-5064

Author(s):

Chittima Sirijerachai ◽

Kanchana Chansung ◽

Arnuparp Lekhakula ◽

Jakrawadee Julamanee ◽

Kitsada Wudhikarn ◽

...

Keyword(s):

T Cell ◽

Complete Remission ◽

Treatment Outcomes ◽

Clinical Features ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Disease Stage ◽

Peripheral T Cell Lymphoma ◽

Angioimmunoblastic T Cell Lymphoma ◽

Multicenter Registry

Abstract OBJECTIVES: To analyze clinical features, treatment outcomes in Thai patients with angioimmunoblastic T cell lymphoma (AITL). PATIENTS AND METHODS: From a nationwide multicenter registry of 4,056 NHL patients in Thailand between 2007 and 2014, there were a total of 54 angioimmunoblastic T cell lymphoma (AITL) patients. The clinical features and treatment outcomes were analyzed. RESULTS: There were a total of 54 cases accounted to the prevalence of 1.2 % of NHL and 12% of peripheral T cell lymphoma. The median age was 59 years (range 35-81). Male: female was 1.5:1. Seventy-eight percent of patients had advanced disease (stage III, IV), 69% had B symptoms, 28% had poor performance status (ECOG > 2) and 61% had elevated serum LDH level. Extranodal involvement was 56 %; the most common sites of which were bone marrow (30%) and liver (19 %). Thirty-five percent of the patients had IPI score > 2 and 7% had PIT >2. Eighty-one percent of patients were treated with chemotherapy of which CHOP/CHOP-like was the main regimen. Of the 43 evaluable patients receiving chemotherapy, complete remission was achieved in 41.9%. Forty-four percent of patients with complete remission had disease progression. With the median follow-up time of 65 months, the 5-year overall survival was comparable to peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), (28% vs. 37%, p=0.7). On multivariate analysis, response to treatment (at least PR) was associated with better outcome (HR 0.13, 95%CI 0.05-0.33, p= 0.000). Patients with PIT > 2 or B symptoms trended to have inferior survival outcome, although statistical significant was not achieve (HR 3.2, 95%CI 0.36-27.95, p=0.3; HR 2.3, 95%CI 0.78-7.31, p=0.13). CONCLUSIONS: The prevalence of Thai patients with AITL was much less than data reported from the international T-cell lymphoma project (18% of T-NHLs) (Vose et al, JCO2008;26:4124-30). The long-term survival was not inferior to patients with PTCL, NOS. Disclosures Khuhapinant: Roche: Honoraria.

Download Full-text